Consistent with our results, MSH6 rs1042821 has previously been associated with increased CRC risk [91,92,93], highly malignant bladder cancer [94], pancreatic cancer [95] and triple negative breast cancer (TNBC) [96]. Here, MSH6 is linked to triple-negative breast carcinoma.